

## COMMENCEMENT OF CHIEF EXECUTIVE OFFICER

**Sydney:** AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX:EIQ) is pleased to confirm that Mr Dustin Haines has commenced in the position of Chief Executive Officer, effective from 10 January 2025, in accordance with the terms of his appointment (refer ASX Announcement 9 October 2024).

With a career in the US healthcare sector spanning more 25 years, including significant executive-level experience, Mr Haines was appointed to advance Echo IQ’s US commercialisation strategy for its EchoSolv-AS technology – a unique AI-based diagnostic tool to aid in the detection of severe Aortic Stenosis.

His appointment followed the achievement of a key regulatory milestone in October 2024 when Echo IQ obtained 510(k) clearance from the US Food & Drug Administration (FDA), allowing for its solution to be marketed to and used by healthcare professionals in the USA (refer ASX Announcement 8 October 2024).

Following FDA clearance, Echo IQ has prioritised efforts to advance its commercialisation strategy in the US market. Work carried out to-date includes the identification of Miscellaneous Code 93799 for EchoSolv-AS, which sets out a target reimbursement rate (on a fee-per-use basis) from insurers to users of the technology – an important step towards full reimbursement status (refer ASX Announcement 9 December 2024).

Mr Haines commences as CEO with a successful track record in overseeing business development, driving revenue growth and bringing products from development to commercialisation, including the obtainment of reimbursement codes.

As a US-based executive with over two decades of experience working in the US healthcare system, Echo IQ aims to leverage Mr Haines’ extensive industry knowledge and strong networks to advance the next phase of its US commercialisation strategy.

### Management commentary:

**Echo IQ Chair, Mr Andrew Grover said:** *“Since Dustin’s appointment in October 2024, he has been working with the incumbent management team to ensure he was across all facets of the business and ready to hit the ground running once his term as CEO commenced. Since achieving FDA Clearance, Echo IQ has already made important advances in its commercialisation strategy*

*for EchoSolv-AS, and we are thrilled to have a CEO of Dustin's calibre to oversee the next phase of our drive towards first revenues in the US market."*

- ENDS -

**Authorised for release by the Board of Directors of Echo IQ Limited.**

**Investor Enquiries:**

Andrew Grover, Executive Chair  
[Andrew.grover@echoiq.ai](mailto:Andrew.grover@echoiq.ai) / [investor@echoiq.ai](mailto:investor@echoiq.ai)

Henry Jordan, Six Degrees Investor Relations  
[Henry.jordan@sdir.com.au](mailto:Henry.jordan@sdir.com.au) / +61 (0) 431 271 538

**ABOUT ECHO IQ**

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.